acf/google-ad-placement

Never miss a trade again with the fastest news alerts in the world!
 This headline only article is a sample of real-time intelligence
 <a href="https://benzinga.grsm.io/headlineonlyarticles3398">Benzinga Pro</a> traders use to win in the markets everyday.
 Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters?
 <a href="https://benzinga.grsm.io/headlineonlyarticles3398">Join 10,000+ serious traders in the Benzinga Pro community!</a>

Biotech

News

General

Salarius Pharmaceuticals Notified By MD Anderson Cancer Center Of Grade 4 Adverse Event In Seclidemstat Clinical Trial; FDA Places Trial On Partial Clinical Hold; No New Patients Enrolled, Current Patients May Continue Treatment; Company To Support Data Analysis And Respond To FDA Queries - Salarius Pharmaceuticals (NASDAQ:SLRX)

Benzinga Newsdesk

Salarius Pharmaceuticals

SLRX

Salarius Pharmaceuticals Notified By MD Anderson Cancer Center Of Grade 4 Adverse Event In Seclidemstat Clinical Trial; FDA Places Trial On Partial Clinical Hold; No New Patients Enrolled, Current Patients May Continue Treatment; Company To Support Data Analysis And Respond To FDA Queries

Comments